Cargando…

In Vitro Activity of Cefepime-Taniborbactam and Comparators against Clinical Isolates of Gram-Negative Bacilli from 2018 to 2020: Results from the Global Evaluation of Antimicrobial Resistance via Surveillance (GEARS) Program

Taniborbactam is a novel cyclic boronate β-lactamase inhibitor in clinical development in combination with cefepime. We assessed the in vitro activity of cefepime-taniborbactam and comparators against a 2018–2020 collection of Enterobacterales (n = 13,731) and Pseudomonas aeruginosa (n = 4,619) isol...

Descripción completa

Detalles Bibliográficos
Autores principales: Karlowsky, James A., Hackel, Meredith A., Wise, Mark G., Six, David A., Uehara, Tsuyoshi, Daigle, Denis M., Cusick, Susan M., Pevear, Daniel C., Moeck, Greg, Sahm, Daniel F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9872668/
https://www.ncbi.nlm.nih.gov/pubmed/36541767
http://dx.doi.org/10.1128/aac.01281-22
_version_ 1784877451653939200
author Karlowsky, James A.
Hackel, Meredith A.
Wise, Mark G.
Six, David A.
Uehara, Tsuyoshi
Daigle, Denis M.
Cusick, Susan M.
Pevear, Daniel C.
Moeck, Greg
Sahm, Daniel F.
author_facet Karlowsky, James A.
Hackel, Meredith A.
Wise, Mark G.
Six, David A.
Uehara, Tsuyoshi
Daigle, Denis M.
Cusick, Susan M.
Pevear, Daniel C.
Moeck, Greg
Sahm, Daniel F.
author_sort Karlowsky, James A.
collection PubMed
description Taniborbactam is a novel cyclic boronate β-lactamase inhibitor in clinical development in combination with cefepime. We assessed the in vitro activity of cefepime-taniborbactam and comparators against a 2018–2020 collection of Enterobacterales (n = 13,731) and Pseudomonas aeruginosa (n = 4,619) isolates cultured from infected patients attending hospitals in 56 countries. MICs were determined by CLSI broth microdilution. Taniborbactam was tested at a fixed concentration of 4 μg/mL. Isolates with cefepime-taniborbactam MICs of ≥16 μg/mL underwent whole-genome sequencing. β-lactamase genes were identified in meropenem-resistant isolates by PCR/Sanger sequencing. Against Enterobacterales, taniborbactam reduced the cefepime MIC(90) value by >64-fold (from >16 to 0.25 μg/mL). At ≤16 μg/mL, cefepime-taniborbactam inhibited 99.7% of all Enterobacterales isolates; >97% of isolates with multidrug-resistant (MDR) and ceftolozane-tazobactam-resistant phenotypes; ≥90% of isolates with meropenem-resistant, difficult-to-treat-resistant (DTR), meropenem-vaborbactam-resistant, and ceftazidime-avibactam-resistant phenotypes; 100% of VIM-positive, AmpC-positive, and KPC-positive isolates; 98.7% of extended-spectrum β-lactamase (ESBL)-positive; 98.8% of OXA-48-like-positive; and 84.6% of NDM-positive isolates. Against P. aeruginosa, taniborbactam reduced the cefepime MIC(90) value by 4-fold (from 32 to 8 μg/mL). At ≤16 μg/mL, cefepime-taniborbactam inhibited 97.4% of all P. aeruginosa isolates; ≥85% of isolates with meropenem-resistant, MDR, and meropenem-vaborbactam-resistant phenotypes; >75% of isolates with DTR, ceftazidime-avibactam-resistant, and ceftolozane-tazobactam-resistant phenotypes; and 87.4% of VIM-positive isolates. Multiple potential mechanisms, including carriage of IMP, certain alterations in PBP3, permeability (porin) defects, and possibly, upregulation of efflux were present in most isolates with cefepime-taniborbactam MICs of ≥16 μg/mL. We conclude that cefepime-taniborbactam exhibited potent in vitro activity against Enterobacterales and P. aeruginosa and inhibited most carbapenem-resistant isolates, including those carrying serine carbapenemases or NDM/VIM metallo-β-lactamases (MBLs).
format Online
Article
Text
id pubmed-9872668
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-98726682023-01-25 In Vitro Activity of Cefepime-Taniborbactam and Comparators against Clinical Isolates of Gram-Negative Bacilli from 2018 to 2020: Results from the Global Evaluation of Antimicrobial Resistance via Surveillance (GEARS) Program Karlowsky, James A. Hackel, Meredith A. Wise, Mark G. Six, David A. Uehara, Tsuyoshi Daigle, Denis M. Cusick, Susan M. Pevear, Daniel C. Moeck, Greg Sahm, Daniel F. Antimicrob Agents Chemother Susceptibility Taniborbactam is a novel cyclic boronate β-lactamase inhibitor in clinical development in combination with cefepime. We assessed the in vitro activity of cefepime-taniborbactam and comparators against a 2018–2020 collection of Enterobacterales (n = 13,731) and Pseudomonas aeruginosa (n = 4,619) isolates cultured from infected patients attending hospitals in 56 countries. MICs were determined by CLSI broth microdilution. Taniborbactam was tested at a fixed concentration of 4 μg/mL. Isolates with cefepime-taniborbactam MICs of ≥16 μg/mL underwent whole-genome sequencing. β-lactamase genes were identified in meropenem-resistant isolates by PCR/Sanger sequencing. Against Enterobacterales, taniborbactam reduced the cefepime MIC(90) value by >64-fold (from >16 to 0.25 μg/mL). At ≤16 μg/mL, cefepime-taniborbactam inhibited 99.7% of all Enterobacterales isolates; >97% of isolates with multidrug-resistant (MDR) and ceftolozane-tazobactam-resistant phenotypes; ≥90% of isolates with meropenem-resistant, difficult-to-treat-resistant (DTR), meropenem-vaborbactam-resistant, and ceftazidime-avibactam-resistant phenotypes; 100% of VIM-positive, AmpC-positive, and KPC-positive isolates; 98.7% of extended-spectrum β-lactamase (ESBL)-positive; 98.8% of OXA-48-like-positive; and 84.6% of NDM-positive isolates. Against P. aeruginosa, taniborbactam reduced the cefepime MIC(90) value by 4-fold (from 32 to 8 μg/mL). At ≤16 μg/mL, cefepime-taniborbactam inhibited 97.4% of all P. aeruginosa isolates; ≥85% of isolates with meropenem-resistant, MDR, and meropenem-vaborbactam-resistant phenotypes; >75% of isolates with DTR, ceftazidime-avibactam-resistant, and ceftolozane-tazobactam-resistant phenotypes; and 87.4% of VIM-positive isolates. Multiple potential mechanisms, including carriage of IMP, certain alterations in PBP3, permeability (porin) defects, and possibly, upregulation of efflux were present in most isolates with cefepime-taniborbactam MICs of ≥16 μg/mL. We conclude that cefepime-taniborbactam exhibited potent in vitro activity against Enterobacterales and P. aeruginosa and inhibited most carbapenem-resistant isolates, including those carrying serine carbapenemases or NDM/VIM metallo-β-lactamases (MBLs). American Society for Microbiology 2022-12-21 /pmc/articles/PMC9872668/ /pubmed/36541767 http://dx.doi.org/10.1128/aac.01281-22 Text en Copyright © 2022 Karlowsky et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Susceptibility
Karlowsky, James A.
Hackel, Meredith A.
Wise, Mark G.
Six, David A.
Uehara, Tsuyoshi
Daigle, Denis M.
Cusick, Susan M.
Pevear, Daniel C.
Moeck, Greg
Sahm, Daniel F.
In Vitro Activity of Cefepime-Taniborbactam and Comparators against Clinical Isolates of Gram-Negative Bacilli from 2018 to 2020: Results from the Global Evaluation of Antimicrobial Resistance via Surveillance (GEARS) Program
title In Vitro Activity of Cefepime-Taniborbactam and Comparators against Clinical Isolates of Gram-Negative Bacilli from 2018 to 2020: Results from the Global Evaluation of Antimicrobial Resistance via Surveillance (GEARS) Program
title_full In Vitro Activity of Cefepime-Taniborbactam and Comparators against Clinical Isolates of Gram-Negative Bacilli from 2018 to 2020: Results from the Global Evaluation of Antimicrobial Resistance via Surveillance (GEARS) Program
title_fullStr In Vitro Activity of Cefepime-Taniborbactam and Comparators against Clinical Isolates of Gram-Negative Bacilli from 2018 to 2020: Results from the Global Evaluation of Antimicrobial Resistance via Surveillance (GEARS) Program
title_full_unstemmed In Vitro Activity of Cefepime-Taniborbactam and Comparators against Clinical Isolates of Gram-Negative Bacilli from 2018 to 2020: Results from the Global Evaluation of Antimicrobial Resistance via Surveillance (GEARS) Program
title_short In Vitro Activity of Cefepime-Taniborbactam and Comparators against Clinical Isolates of Gram-Negative Bacilli from 2018 to 2020: Results from the Global Evaluation of Antimicrobial Resistance via Surveillance (GEARS) Program
title_sort in vitro activity of cefepime-taniborbactam and comparators against clinical isolates of gram-negative bacilli from 2018 to 2020: results from the global evaluation of antimicrobial resistance via surveillance (gears) program
topic Susceptibility
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9872668/
https://www.ncbi.nlm.nih.gov/pubmed/36541767
http://dx.doi.org/10.1128/aac.01281-22
work_keys_str_mv AT karlowskyjamesa invitroactivityofcefepimetaniborbactamandcomparatorsagainstclinicalisolatesofgramnegativebacillifrom2018to2020resultsfromtheglobalevaluationofantimicrobialresistanceviasurveillancegearsprogram
AT hackelmereditha invitroactivityofcefepimetaniborbactamandcomparatorsagainstclinicalisolatesofgramnegativebacillifrom2018to2020resultsfromtheglobalevaluationofantimicrobialresistanceviasurveillancegearsprogram
AT wisemarkg invitroactivityofcefepimetaniborbactamandcomparatorsagainstclinicalisolatesofgramnegativebacillifrom2018to2020resultsfromtheglobalevaluationofantimicrobialresistanceviasurveillancegearsprogram
AT sixdavida invitroactivityofcefepimetaniborbactamandcomparatorsagainstclinicalisolatesofgramnegativebacillifrom2018to2020resultsfromtheglobalevaluationofantimicrobialresistanceviasurveillancegearsprogram
AT ueharatsuyoshi invitroactivityofcefepimetaniborbactamandcomparatorsagainstclinicalisolatesofgramnegativebacillifrom2018to2020resultsfromtheglobalevaluationofantimicrobialresistanceviasurveillancegearsprogram
AT daigledenism invitroactivityofcefepimetaniborbactamandcomparatorsagainstclinicalisolatesofgramnegativebacillifrom2018to2020resultsfromtheglobalevaluationofantimicrobialresistanceviasurveillancegearsprogram
AT cusicksusanm invitroactivityofcefepimetaniborbactamandcomparatorsagainstclinicalisolatesofgramnegativebacillifrom2018to2020resultsfromtheglobalevaluationofantimicrobialresistanceviasurveillancegearsprogram
AT peveardanielc invitroactivityofcefepimetaniborbactamandcomparatorsagainstclinicalisolatesofgramnegativebacillifrom2018to2020resultsfromtheglobalevaluationofantimicrobialresistanceviasurveillancegearsprogram
AT moeckgreg invitroactivityofcefepimetaniborbactamandcomparatorsagainstclinicalisolatesofgramnegativebacillifrom2018to2020resultsfromtheglobalevaluationofantimicrobialresistanceviasurveillancegearsprogram
AT sahmdanielf invitroactivityofcefepimetaniborbactamandcomparatorsagainstclinicalisolatesofgramnegativebacillifrom2018to2020resultsfromtheglobalevaluationofantimicrobialresistanceviasurveillancegearsprogram